# US 2024/0094224 A1 · Anti-microbial peptide (amp) signatures for diagnostics, stratification, and treatment of microbiome-associated disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0094224 A1
- Document ID: US20240094224A1
- Status: Published application
- Kind: A1
- Application number: 18/522,466
- Filed: 2023-11-29
- Published: 2024-03-21
- Earliest claimed: 2021-05-30
- Assignees: Yeda Research and Development Co. Ltd.
- Applicants: Yeda Research and Development Co. Ltd.
- Inventors: Eran ELINAV; Alon SAVIDOR
- Web page: https://patentgrep.com/patent/US20240094224A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- G01N 2333/4721: Cationic antimicrobial peptides, e.g. defensins
- G01N 2800/04: Endocrine or metabolic disorders
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N 2800/7095: Inflammation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Proxies for physiological states of tissue are provided. Accordingly, there are provided methods of determining host AMP landscape, establishing a profile indicative of tissue status, and identifying proxies for tissue status in AMP profiles of samples of secretions, exudates and/or excretions of the tissue. Also provided are methods for determination of disease severity and chronology.

## Claims

### Claim 1

A method of determining presence of Inflammatory Bowel Disease (IBD) in the gut mucosa of a subject, the method comprising measuring levels of azurocidin (AZU) in a stool sample from said subject, wherein increased levels of AZU in said stool sample compared to normal levels is indicative of IBD.

### Claim 2 (depends on 1)

The method of claim 1, wherein said increased levels of AZU in said stool sample is levels greater than that in stool sample of a subject free of IBD.

### Claim 3 (depends on 1)

The method of claim 1, wherein said determining said levels of AZU is effected on a protein extract of said stool sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein said stool sample is depleted of membrane proteins and membrane-bound organelle proteins.

### Claim 5 (depends on 1)

The method of claim 1, wherein said subject is suffering from IBD symptoms selected from the group consisting of weight loss, bloody diarrhea, destruction of epithelial cells, and dysregulation of mucosal immune responses.

### Claim 6 (depends on 1)

The method of claim 1, wherein said AZU is identified by liquid chromatography, mass spectrometry or a combination of liquid chromatography and mass spectrometry.

### Claim 7 (depends on 1)

The method of claim 1, wherein said AZU is identified by mass spectrometry-based label free quantification (LFQ).

### Claim 8 (depends on 1)

The method of claim 1, wherein said AZU is identified by AMP binding moieties.

### Claim 9 (depends on 8)

The method of claim 8, wherein said AMP binding moieties are immobilized on an array.

### Claim 10

A kit for determining the presence of IBD in the gut, comprising at least one AZU-binding moiety.

### Claim 11 (depends on 10)

The kit of claim 10, wherein said at least one binding moiety is selected from the group consisting of antibodies, aptamers and ligands.

### Claim 12

A method of treating IBD in a subject suspected of having IBD, comprising:
(i) measuring the level of AZU in a stool sample of said subject;
(ii) determining the presence of IBD in the gut of the subject based on the level of AZU in said stool sample being greater than the level of AZU in a stool sample of a normal healthy subject; and
(iii) treating said IBD in said subject confirmed as having IBD.

### Claim 13

A method of monitoring response of a subject to treatment for IBD, comprising:
(i) determining the presence of IBD in the gut of the subject by measuring the level of AZU in a stool sample of said subject,
(ii) initiating treatment for IBD,
(iii) measuring the level of AZU in a second stool sample of said subject at a predetermined interval from step (ii),
(iv) comparing the levels of AZU from step (i) and step (iii), and
(v) determining the response of the subject according to the difference in AZU levels in the first and second stool samples.

### Claim 14 (depends on 13)

The method of claim 13, further comprising adjusting said treatment of said subject for IBD according to the response monitored in step (v).

### Claim 15 (depends on 13)

The method of claim 13, wherein the presence of IBD in the gut of said subject is determined based on the level of AZU in said stool sample being greater than the level of AZU in a stool sample of a normal healthy subject.

### Claim 16 (depends on 13)

The method of claim 13, further comprising additional measurements of AZU in at least one additional stool sample at at least one predetermined interval from said second stool sample;
comparing the levels of AZU with those from previous levels; and
determining the response of the subject according to the difference in AZU levels in the previous and additional stool samples.
